Host-directed Immunotherapy

About Affirma Biotech

Affirma Biotech is a private, preclinical-stage Spanish biotech founded in 2018, targeting severe respiratory infections through orally administered host-directed immunotherapies. The company has demonstrated in vivo proof-of-concept in influenza and bacterial infection models and has secured seed funding to advance its programs. Its strategy addresses the critical unmet needs of antimicrobial resistance and suboptimal outcomes in severe infections by modulating the patient's immune response rather than directly targeting pathogens.

About Affirma Biotech

Affirma Biotech is a private, preclinical-stage Spanish biotech founded in 2018, targeting severe respiratory infections through orally administered host-directed immunotherapies. The company has demonstrated in vivo proof-of-concept in influenza and bacterial infection models and has secured seed funding to advance its programs. Its strategy addresses the critical unmet needs of antimicrobial resistance and suboptimal outcomes in severe infections by modulating the patient's immune response rather than directly targeting pathogens.

Therapeutic Areas